As more people try weight-loss drugs like Wegovy, some skip the brand name and buy compounded semaglutide from online pharmacies. But some of these may not follow state and federal standards.
America is a land of contradictions; while we're known as a nation that loves to eat, we also live within a culture that has long valued thinness as the utmost beauty standard.
Over the last several years the body positivity movement has pushed back on that notion. But then came a new class of weight-loss drugs.
New York Magazine contributing writer Samhita Mukhopadhyay grapples with the possible future of a movement like this in her recent article, So Was Body Positivity All A Big Lie?
She joins All Things Considered host Juana Summers to discuss the ever-evolving conversation on health, size, and whose business that is in the first place.
For sponsor-free episodes of Consider This, sign up for Consider This+ via Apple Podcasts or at plus.npr.org.
The announcement comes amid falling profits for the company. WeightWatchers has been facing declining stock prices since November as weight loss drugs, known as GLP1s, have soared in popularity.
A doctor argues that the current focus on fighting obesity with drugs like Ozempic ignores the bigger picture: We need a medical system and society that support healthy life habits.
A physician decided to stop talking to patients about weight, and focus on health instead. But the new weight-loss drugs forced her to rethink how to help patients without feeding into stigma.
People taking weight-loss drugs Ozempic and Wegovy report a dampening of the urge to drink. Here's how the drugs curb cravings and what that could mean for helping treat addiction.
New weight-loss medications and bariatric surgery have the potential to spare children health and social problems. But some parents think they're sending kids the wrong message about their bodies.
There's already a huge demand for existing weight-loss drugs, so the new medication is highly anticipated. Obesity affects an estimated 650 million adults globally.
The new weight-loss drugs can be life-changing for people facing health conditions worsened by obesity, but price and spotty insurance coverage may keep them out of reach.
